587 related articles for article (PubMed ID: 8968099)
1. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
2. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
3. Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy.
Blum S; Milesi R; Tratkiewicz J; Olive D; Gallati H; Cerottini JC; von Fliedner V
Ther Immunol; 1994 Jun; 1(3):143-52. PubMed ID: 7584490
[TBL] [Abstract][Full Text] [Related]
4. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
5. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
6. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
8. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
[TBL] [Abstract][Full Text] [Related]
9. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
10. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells.
Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809
[TBL] [Abstract][Full Text] [Related]
11. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies.
Renner C; Jung W; Sahin U; van Lier R; Pfreundschuh M
Eur J Immunol; 1995 Jul; 25(7):2027-33. PubMed ID: 7621876
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
13. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
14. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
15. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
16. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
17. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
18. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
19. CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex.
Siefken R; Kurrle R; Schwinzer R
Cell Immunol; 1997 Feb; 176(1):59-65. PubMed ID: 9070318
[TBL] [Abstract][Full Text] [Related]
20. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]